Bharath Kumar Velmurugan¹, Shu Hui Lin^2,3,4, Chih-Yang Huang^5,6,7,8,9,10, Ming-Ju Hsieh^9,11,12,*, Rathinasamy Baskaran^10,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083159 - 13 August 2026

Abstract Mitochondria are central regulators of cellular metabolism and survival and play a pivotal role in cancer development and progression through the production of reactive oxygen species (ROS), control of calcium homeostasis, regulation of autophagy, and modulation of cell death pathways. Mitochondria-derived ROS (mtROS) act as signaling mediators that influence tumor initiation, proliferation, metabolic reprogramming, metastasis, and therapeutic resistance by altering redox homeostasis, damaging mitochondrial DNA, and reshaping the tumor microenvironment. In addition to meeting the bioenergetic and biosynthetic requirements of rapidly proliferating cancer cells, mitochondrial metabolism modulates immune responses and supports cancer cell adaptation to More >

Wen Gao^1,2, Xingyu Zheng^1,2, Yanan Hu^1,2, Rui Zou³, Yongan Zhou⁴, Xiang Song^2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082652 - 13 August 2026

Abstract Background: As a core component of the immunoproteasome, the β1i subunit (proteasome 20S subunit beta 9, PSMB9) is involved in antigen processing and presentation and regulates anti-tumor immune responses. PSMB9 is aberrantly overexpressed in colorectal cancer. However, the precise mechanisms through which PSMB9 contributes to the initiation, progression, and immune regulation of colorectal cancer remain unclear. This study aims to investigate the expression characteristics and biological functions of PSMB9 in colorectal cancer, and to further elucidate the molecular pathways underlying its role in colorectal cancer initiation and progression. The findings are expected to provide a theoretical… More >

Yanhong Wang^1,#, Junbo Liu^2,#, Qiaoping Xu^3,#, Zhao Ma^4,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082432 - 13 August 2026

Abstract In renal cell carcinoma (RCC), alterations in cellular metabolism are a defining feature, among which impaired mitochondrial function stands out as a key factor influencing both tumor aggressiveness and patient responses to therapy. The aim of this review is to systematically synthesize current knowledge on the role of mitochondrial dysfunction in RCC pathogenesis and to explore emerging therapeutic strategies targeting mitochondrial vulnerabilities. This comprehensive analysis examines the integrated dysregulation of core mitochondrial processes—bioenergetic metabolism, organelle dynamics, programmed cell death pathways, redox homeostasis, and selective autophagy—in driving RCC pathogenesis. Our synthesis reveals how genetic drivers, molecular… More >

Lucrezia Paradisi, Lorenza Trabalzini, Federica Finetti^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082155 - 13 August 2026

Abstract Cytoskeletal reorganization is fundamental to essential cellular processes, including shape maintenance, migration, adhesion cytokinesis, and phagocytosis, and its dysregulation is a hallmark of tumor progression. In cancer cells, altered cytoskeletal dynamics promote invasion and genomic instability resulting from mitotic defects. The actin and microtubule cytoskeletons are highly dynamic polymer networks that organize intracellular architecture, establish polarity, and generate the mechanical forces required for cell division and motility. Their dysregulation disrupts normal cell behavior and facilitates tumor invasion and metastasis. The cytoskeleton therefore represents a key source of potential therapeutic targets for inhibiting metastatic dissemination. This More >

Estelle C. I. D. Schad^1,#, Janet P. Raja Xavier^1,#, Hortense Decool¹, Marcel Arnholdt¹, Franziska Keßler¹, Jan Schöttke¹, Sara Y. Brucker¹, Ernst Oberlechner¹, Johanna Laupp¹, Martin Weiss^1,2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.081755 - 13 August 2026

Abstract Background: Vulvar squamous cell carcinoma (VSCC) is a rare, but increasingly prevalent malignancy with limited therapeutic options in the advanced disease state. Cisplatin-based chemoradiation remains the standard of care but is constrained by cumulative toxicity. Precancerous lesions, including high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN), similarly require effective yet tolerable treatments. Low-thermal Argon plasma devitalization (ltAPD), a source of reactive oxygen and nitrogen species (RONS), has emerged as a promising approach for redox-based tumor modulation. This study aimed to evaluate the anti-tumor efficacy of two plasma modalities, plasma-treated solution (PTS) and plasma-treated… More >

Carlo Signorelli^1,*, Michele Basso², Annunziato Anghelone², Maria Alessandra Calegari², Alessandro Passardi³, Chiara Gallio³, Alessandro Bittoni³, Jessica Lucchetti⁴, Lorenzo Angotti⁴, Emanuela Di Giacomo⁴, Ina Valeria Zurlo⁵, Cristina Morelli⁶, Emanuela Dell’Aquila⁷, Adele Artemi⁷, Donatello Gemma⁸, Domenico Cristiano Corsi⁹, Alessandra Emiliani⁹, Marta Ribelli⁹, Federica Mazzuca¹⁰, Giulia Arrivi¹⁰, Federica Zoratto¹¹, Maria Grazia Morandi¹², Fiorenza Santamaria^13,14, Manuela Dettori¹⁵, Antonella Cosimati¹⁶, Rosa Saltarelli¹⁷, Alessandro Minelli¹⁸, Emanuela Lucci-Cordisco¹⁹, Mario Giovanni Chilelli¹

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080964 - 13 August 2026

Abstract Background: Trifluridine/tipiracil (T) is a standard treatment for refractory metastatic colorectal cancer (mCRC). In randomized trials, treatment-emergent neutropenia has been associated with improved outcomes, suggesting a potential link with drug activity. However, evidence from routine clinical practice remains limited. This sub-analysis of the multicenter ReTrITA study evaluated the association between severe neutropenia and clinical outcomes in a real-world setting. Methods: Patients with refractory mCRC treated with T within the ReTrITA cohort were included. Patients were stratified according to the occurrence of grade 3–4 neutropenia. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier… More >

Yongpan Wang^1,#, Weiqiang Huang^1,#, Qizhuan Lin², Helei Cai², Fengjin Dai³, Haiqing Gu¹, Shunyan Yu¹, Libo Jin^2,*, Renyi Peng^2,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080113 - 13 August 2026

Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor clinical outcomes. Owing to the absence of estrogen receptors, progesterone receptors, and Human Epidermal Growth Factor Receptor 2 (HER2) expression, TNBC shows limited responsiveness to conventional endocrine and targeted therapies. This subtype exhibits strong heterogeneity, a high propensity for metastasis, and a tendency to develop acquired drug resistance. Its survival and progression largely rely on non-classical signaling pathways, including Epidermal growth factor receptor (EGFR), Phosphoinositide 3-kinase/Protein Kinase B (PI3K/AKT), and Notch, which collectively impose substantial challenges to clinical management. In recent… More >

Xuan Chen, Chao Luo, Wei Wen^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079753 - 13 August 2026

Abstract This article systematically elaborates on the dual role of DNA methylation in the initiation and progression of gastric cancer and its potential clinical applications in precision oncology. As a core epigenetic mechanism, DNA methylation drives the multistage development of gastric cancer through the coordinated dysregulation of genome-wide hypomethylation and promoter-specific hypermethylation, playing a key role in chronic inflammation and epigenetic reprogramming, particularly in the context of Helicobacter pylori infection. The article focuses on analyzing the central pathogenic mechanisms of DNA methylation, including the silencing of tumor suppressor genes, induction of genomic instability, promotion of the CpG More >

Emmanuel Naveen Raj^1,#, Chia-Jung Li^1,2,3,4,5,#, Shih-Hsuan Cheng¹, Su-Boon Yong^6,7, Zhi-Hong Wen^3,8, An-Jen Chiang^1,9,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079551 - 13 August 2026

Abstract Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. Methods: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in… More > Graphic Abstract

Tanzila Saba¹, Muhammad Mujahid¹, Faten S. Alamri^2,*, Roaa Khalil Mohamed Ali Abed³

CMES-Computer Modeling in Engineering & Sciences, Vol.148, No.1, 2026, DOI:10.32604/cmes.2026.084816 - 27 July 2026

Abstract In the era of artificial intelligence, pattern recognition techniques have become fundamental in advancing medical image processing, diagnosis, and automated disease classification systems. Among various clinical challenges, breast cancer is the second most dangerous leading cause of death in women worldwide. Early and accurate detection of breast cancer is crucial to develop advanced diagnostic methods to control further loss or reduce mortality rates. This study proposes a dynamic graph multi-scale network for breast cancer diagnosis, integrated with multi-scale convolutional feature extraction, a squeeze-and-excitation block, and a graph convolutional network to jointly model local spatial features… More > Graphic Abstract